Printer Friendly
The Free Library
14,587,945 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Dainippon Sumitomo Pharma, ASKA Pharmaceutical to Dissolve Dealing Contract.


Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, Jan 26, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Dainippon Sumitomo Pharma and ASKA ASKA Anti-Slipknot Army  Pharmaceutical jointly announced on January 25 that they have agreed to dissolve A Web site design technique borrowed from the film and video industry in which the transition between two Web pages is represented visually by one page fading into another. Also known as a "soft cut," the result is achieved in the HTML coding of the images to gradual pre-determined  their current dealing contract as o March 31, as requested by ASKA Pharmaceutical.

Since October 1982, Dainippon Sumitomo Pharma has been marketing ASKA's products. Going forward, ASKA Pharmaceutical will only supply its products to Takeda Pharmaceutical.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jan 28, 2006
Words:69
Previous Article:Yano Research Institute Releases Report on Japanese Pharmaceutical Market.
Next Article:Fuji Photo Film to Release Compact Digital X-ray System in February.



Related Articles
Dainippon Sumitomo Pharma Kicks off Operations.
Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate.
Ono Pharmaceutical, Dainippon Sumitomo Pharma to Enter into Joint Development and Marketing Agreement for Limaprost Alfadex, Oral PGE1 Derivative.
Dainippon Sumitomo Pharma Receives Approval for Orally Disintegrating Formulation of Amlodin, Hypertension/Angina Pectoris Treatment.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Dainippon Sumitomo Pharma Announces Results of Clinical Trial of Mosapride Citrate.
Dainippon Sumitomo Pharma Licenses Precursor of Norepinephrine to Chelsea Therapeutics International.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Sumitomo Chemical Reports Consolidated Financial Results For the Nine Months Ended December 31, 2006.
Dainippon Sumitomo Pharma Announces Launch of "Replagal(R) 3.5 mg" for Anderson-Fabry Disease.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles